You just read:

MEI Pharma Presents Updated Clinical Data from the ME-401 Phase 1b study in Patients with Indolent B-cell Malignancies at the 2019 International Conference on Malignant Lymphoma (ICML)

News provided by

MEI Pharma, Inc.

Jun 22, 2019, 02:30 ET